1Hosaka M.Antibacterial property and clinical effect of gatifloxacin,a novel quinolone antibacterial agent[J].Nippon Yakurigaku Zasshi.2003,Jun;12(6):447～56.
2Sadeghi M,Daniel V,Naujokat C,Wiesel M,Hergesell O,Opelz G.Strong inflammatory cytokine response in male and strong anti-inflammatory response in female kidney transplant recipients with urinary tract infection[J].Transpl Int.2005,Feb;18(2):177～85.
3Gaines KK.What's new about gatifloxacin (Tequin)?[J]. Urol Nurs.2002,Oct;22(5):343～5.
4Cox CE Marbury TC,Pittman WG,Brown GL,Auerbach SM,Fox BC,Yang JY.A randomized,double-blind,multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis[J].Clin Ther.2002,Feb;24(2):223～36.
5Leibovitz E,Piglansky L,Raiz S,Greenberg D,Hamed KA,Ledeine JM,Press J,Leiberman A,Echols RM,Pierce PF,Jacobs MR,Dagan R.Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media:an open label noncomparative,double tympanocentesis study[J].Pediatr Infect Dis J.2003,22(11):943～9.
6Jones RN.Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins[J].Am J Heath Syst Pharm,1995,52(suppl 2):S29-S33.
7Burgess DS,Hasting RW.Activity of piperacillin/tazobactam in combination with amikacin ciprofloxacin and trovafloxacin against Pseudomonas aeruginosa by time-kill[J].Diagn Microbial Infect Dis,2000,38(1):37-41.
